SI2205244T1 - Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni - Google Patents

Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni

Info

Publication number
SI2205244T1
SI2205244T1 SI200831093T SI200831093T SI2205244T1 SI 2205244 T1 SI2205244 T1 SI 2205244T1 SI 200831093 T SI200831093 T SI 200831093T SI 200831093 T SI200831093 T SI 200831093T SI 2205244 T1 SI2205244 T1 SI 2205244T1
Authority
SI
Slovenia
Prior art keywords
phenylcurea
ylc
benzothiazol
isoxazol
morpholin
Prior art date
Application number
SI200831093T
Other languages
English (en)
Slovenian (sl)
Inventor
Joyce K. James
Shawn R. Eichelberger
Traci L. Savall
Original Assignee
Ambit Biosciences Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences Corporation filed Critical Ambit Biosciences Corporation
Publication of SI2205244T1 publication Critical patent/SI2205244T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
SI200831093T 2007-11-08 2008-11-07 Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni SI2205244T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US258307P 2007-11-08 2007-11-08
US580307P 2007-12-07 2007-12-07
US9867608P 2008-09-19 2008-09-19
US11206008P 2008-11-06 2008-11-06
PCT/US2008/012539 WO2009061446A1 (en) 2007-11-08 2008-11-07 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
EP08847113.1A EP2205244B1 (en) 2007-11-08 2008-11-07 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy-)imidazo-[2,1-b]-[1,3]-benzothiazol-2-yl]-phenyl}urea to treat proliferative disease

Publications (1)

Publication Number Publication Date
SI2205244T1 true SI2205244T1 (sl) 2013-12-31

Family

ID=40262072

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831093T SI2205244T1 (sl) 2007-11-08 2008-11-07 Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni

Country Status (18)

Country Link
US (1) US7968543B2 (enExample)
EP (2) EP2205244B1 (enExample)
JP (2) JP5645667B2 (enExample)
KR (2) KR20150105494A (enExample)
CN (1) CN101835472A (enExample)
AR (1) AR069244A1 (enExample)
AU (1) AU2008325141B2 (enExample)
CA (1) CA2696807C (enExample)
CY (1) CY1114853T1 (enExample)
DK (1) DK2205244T3 (enExample)
ES (1) ES2436266T3 (enExample)
HR (1) HRP20131083T1 (enExample)
MX (1) MX2010002396A (enExample)
PL (1) PL2205244T3 (enExample)
PT (1) PT2205244E (enExample)
SI (1) SI2205244T1 (enExample)
TW (1) TW200924756A (enExample)
WO (1) WO2009061446A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI409267B (zh) * 2006-03-17 2013-09-21 Ambit Biosciences Corp 治療疾病用之咪唑并噻唑化合物
KR101572701B1 (ko) 2007-09-19 2015-11-27 암비트 바이오사이언시즈 코포레이션 Ｎ-(5-ｔｅｒｔ-부틸-이속사졸-3-일)-Ｎ'-[4-[7-(2-모르폴린-4-일-에톡시)이미다조[2,1-Ｂ][1,3]벤조티아졸-2-일]페닐]우레아를 포함하는 고체 형태, 그의 조성물 및 그의 용도
MX2011009989A (es) 2009-03-23 2011-10-14 Ambit Biosciences Corp Metodos de tratamiento utilizando terapia de combinacion.
SMT202000092T1 (it) * 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
CA2778940C (en) 2009-11-05 2018-10-16 Ambit Biosciences Corp. Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives
HUE045270T2 (hu) 2010-01-05 2019-12-30 Inst Nat Sante Rech Med FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
CN103172648B (zh) * 2011-12-20 2016-05-25 上海迪诺医药科技有限公司 三杂环衍生物、制备方法及应用
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
CN104513252B (zh) * 2013-09-26 2017-11-10 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
BR112017002001B1 (pt) 2014-07-31 2022-10-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compostos e composição farmacêutica
AU2015369809B2 (en) 2014-12-22 2022-03-17 Genzyme Corporation Methods of culturing a mammalian cell
CA2976752C (en) 2015-02-20 2019-12-17 Daiichi Sankyo Company, Limited Method for treating cancer by combined use
US10278979B2 (en) * 2015-03-11 2019-05-07 Riken Therapeutic agent for intractable leukemia
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN113966331B (zh) * 2020-03-11 2024-04-12 暨南大学 含脲结构的三芳环化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233903A (en) * 1880-11-02 Velocipede
US233906A (en) * 1880-11-02 Combined stirrer and thermometer
US994635A (en) * 1911-01-10 1911-06-06 Harry C Buhoup Car-truck.
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
TWI409267B (zh) 2006-03-17 2013-09-21 Ambit Biosciences Corp 治療疾病用之咪唑并噻唑化合物
KR101572701B1 (ko) * 2007-09-19 2015-11-27 암비트 바이오사이언시즈 코포레이션 Ｎ-(5-ｔｅｒｔ-부틸-이속사졸-3-일)-Ｎ'-[4-[7-(2-모르폴린-4-일-에톡시)이미다조[2,1-Ｂ][1,3]벤조티아졸-2-일]페닐]우레아를 포함하는 고체 형태, 그의 조성물 및 그의 용도

Also Published As

Publication number Publication date
PL2205244T3 (pl) 2014-01-31
JP5645667B2 (ja) 2014-12-24
MX2010002396A (es) 2010-04-01
US7968543B2 (en) 2011-06-28
AU2008325141A1 (en) 2009-05-14
TW200924756A (en) 2009-06-16
CA2696807A1 (en) 2009-05-14
HRP20131083T1 (hr) 2013-12-20
KR20100075853A (ko) 2010-07-05
DK2205244T3 (da) 2013-11-25
EP2205244A1 (en) 2010-07-14
ES2436266T3 (es) 2013-12-30
PT2205244E (pt) 2013-11-26
CY1114853T1 (el) 2016-12-14
WO2009061446A1 (en) 2009-05-14
AU2008325141B2 (en) 2014-03-20
CN101835472A (zh) 2010-09-15
KR20150105494A (ko) 2015-09-16
AR069244A1 (es) 2010-01-06
EP2596795A1 (en) 2013-05-29
CA2696807C (en) 2017-11-28
EP2205244B1 (en) 2013-08-21
KR101578481B1 (ko) 2015-12-17
JP2014221765A (ja) 2014-11-27
JP2011503063A (ja) 2011-01-27
US20090123418A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
EA201791669A3 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
ZA201100034B (en) Pharmaceutical compositions for treatment of parkinson's disease
ZA200907137B (en) Novel N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
HUE050319T2 (hu) Kompozíciók és eljárások alkoholfogyasztással kapcsolatos rendellenességek, fájdalom és más betegségek kezelésére
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
IL202083A0 (en) Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
EP2271352A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASE
ZA201103516B (en) Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof
TNSN08506A1 (en) Substituted carboxamides
PL2148676T3 (pl) Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
IL213703A0 (en) Compounds and methods for the treatment of pain and other diseases
PL1818064T3 (pl) Sposoby traktowania skóry w celu wzmocnienia jej leczenia terapeutycznego
EP2517704A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE AND METHOD OF MAKING SAME
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
EP1846037A4 (en) METHODS OF TREATING VARIOUS CONDITIONS BY ADMINISTERING L-ARGININE WITH PROLONGED RELEASE
IL209804A0 (en) Pharmaceutical compositions for treatment of parkinson's disease
IL196824A0 (en) Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy
PL383271A1 (pl) Kompozycja farmaceutyczna przydatna w leczeniu chorób wirusowych
PL383272A1 (pl) Kompozycja farmaceutyczna przydatna w leczeniu chorób wirusowych
GB0705001D0 (en) Composition and method for treatment of drug dependence and disease